With the acquisition, Olympus’ dual action lithotripsy systems ShockPulse-SE and CyberWand which were previously manufactured by Cybersonics will be serviced and manufactured by the Olympus Surgical Technologies America subsidiary.
Olympus said that the acquisition will not affect customers in terms of resources, services or contacts, and that it will release more details of the acquisition in the future.
“We are thrilled to acquire Cybersonics’ lithotripsy systems and add them to our already powerful urology portfolio. This acquisition supports one of our key strategic initiatives to drive growth in this core part of our business as we establish our design and production competence in lithotripsy, and allows us to leverage our internal manufacturing expertise to better meet the needs of medical professionals and patients,” OSTA prez Joe Doherty said in a prepared statement.
“We have enjoyed a longstanding, mutually beneficial relationship with Olympus. As we look to the future, it makes sense that Olympus take over the manufacturing and design of the lithotripsy products in order to provide a seamless experience to the end customer,” Cybersonics prez Geoff Bondsaid in a press release.
Last month,the FDA issued warning letters to Olympus, Fujifilm Holdings (TSE:4901), and Hoya‘s Pentax Medical over failures to comply with federal orders to conduct postmarket surveillance studies to assess the effectiveness of reprocessing duodenoscopes.